# Ind-Swift Laboratories (NSE: INDSWFTLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/INDSWFTLAB · Pivot · prices to 22 Oct 2026

Ind-Swift Laboratories (NSE: INDSWFTLAB) closed at ₹347.05 on 22 Oct 2026, up 1.92% on the day. With a market capitalisation of ₹3,018 Cr, it ranks 963rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 71.6× trailing earnings, against a return on equity of −70.5% in FY25. Over the past year the share price has risen 240.9%. Its 52-week range is ₹87.15 (31 Dec 2025) to ₹424.75 (30 Sep 2026); the last close is 18.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹170 Cr (+22.8% year on year) and net profit ₹15 Cr (−93.2%), on a consolidated basis. Promoters held 42.93% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹347.05 |
| Market cap | ₹3,018 Cr |
| P/E (trailing) | 71.6 |
| ROE | −70.5% (FY25) |
| ROCE | 10.5% (FY25) |
| Debt to equity | -2.17 |
| 52-week high | ₹424.75 (30 Sep 2026) |
| 52-week low | ₹87.15 (31 Dec 2025) |
| 1-year return | +240.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹170 Cr | +22.8% | ₹15 Cr | −93.2% | ₹1.81 |
| Q3 FY26 | ₹151 Cr | +1,641.9% | ₹10 Cr | — | ₹1.17 |
| Q2 FY26 | ₹153 Cr | +1,176.3% | ₹8 Cr | +1,910.0% | ₹1.00 |
| Q1 FY26 | ₹153 Cr | +360.4% | ₹9 Cr | +756.4% | ₹1.28 |
| Q4 FY25 | ₹138 Cr | −64.9% | ₹222 Cr | −6.9% | ₹32.96 |
| Q3 FY25 | ₹9 Cr | −97.0% | −₹0 Cr | −100.1% | — |
| Q2 FY25 | ₹12 Cr | −95.9% | ₹0 Cr | −98.7% | ₹0.07 |
| Q1 FY25 | ₹33 Cr | −89.3% | ₹1 Cr | −94.2% | ₹0.16 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹515 Cr | ₹283 Cr |
| FY24 | ₹502 Cr | ₹14 Cr |
| FY23 | ₹411 Cr | ₹26 Cr |
| FY22 | ₹398 Cr | −₹20 Cr |
| FY18 | ₹271 Cr | −₹54 Cr |
| FY17 | ₹267 Cr | −₹364 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 42.93%
- Foreign institutions: 10.70%
- Domestic institutions: 0.17%
- Non-institutions: 46.20%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Unichem Laboratories](https://app.pivotnow.in/stock/UNICHEMLAB) | ₹495.95 | ₹3,492 Cr | 13.8 | — |
| [Aarti Drugs](https://app.pivotnow.in/stock/AARTIDRUGS) | ₹381.15 | ₹3,479 Cr | 17.9 | — |
| [Solara Active Pharma Sciences](https://app.pivotnow.in/stock/SOLARA) | ₹650.75 | ₹3,140 Cr | — | — |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹265.45 | ₹2,972 Cr | 17.6 | — |
| [Shukra Pharma](https://app.pivotnow.in/stock/SHUKRAPHAR) | ₹63.62 | ₹2,797 Cr | 127.2 | — |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |

## Questions and answers

### What is the share price of Ind-Swift Laboratories today?

Ind-Swift Laboratories (NSE: INDSWFTLAB) last closed at ₹347.05 on 22 Oct 2026. Its 52-week high is ₹424.75 and its 52-week low is ₹87.15.

### What is the market cap of Ind-Swift Laboratories?

Ind-Swift Laboratories' market capitalisation is ₹3,018 Cr (₹3,018 Cr) at the 22 Oct 2026 close, ranking 963rd among the NSE companies Pivot tracks.

### What is the P/E ratio of Ind-Swift Laboratories?

Ind-Swift Laboratories trades at a trailing P/E of 71.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 17.9.

### What is the ROE and ROCE of Ind-Swift Laboratories?

Return on equity was −70.5% in FY25 and return on capital employed was 10.5% in FY25 (consolidated figures).

### Is Ind-Swift Laboratories a debt-free company?

Ind-Swift Laboratories is close to debt-free: its debt-to-equity ratio was -2.17 in FY25.

### What were Ind-Swift Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Ind-Swift Laboratories reported revenue of ₹170 Cr, +22.8% year on year, and net profit of ₹15 Cr, −93.2% year on year.

### How has Ind-Swift Laboratories stock performed over the last year?

Ind-Swift Laboratories' share price has risen 240.9% over the past year, +49.0% over three months and −9.2% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Ind-Swift Laboratories?

As of 30 Jun 2026: promoters 42.93%, foreign institutions 10.70%, domestic institutions 0.17%, non-institutions 46.20%.

### Who are Ind-Swift Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Ind-Swift Laboratories by market cap are Unichem Laboratories, Aarti Drugs, Solara Active Pharma Sciences, Advanced Enzyme Technologies, Shukra Pharma and Dishman Pharma.

### Is Ind-Swift Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Ind-Swift Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDSWFTLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.